XLO
Company Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 43.77M | 6.34M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (35.04M) | (58.24M) | (76.40M) | (88.22M) | (75.80M) | (55.22M) | (17.31M) |
| EPS | -4.19 | -15.26 | -38.92 | -45.08 | -189.28 | -1475.88 | -592.06 |
| Free Cash Flow | (5.51M) | (18.41M) | (69.11M) | (77.59M) | (81.85M) | (38.28M) | (18.56M) |
| FCF / Share | -0.07 | -4.82 | -35.19 | -39.66 | -204.40 | -1023.15 | -634.79 |
| Operating CF | (4.99M) | (18.38M) | (68.62M) | (75.72M) | (80.75M) | (36.09M) | (17.84M) |
| Total Assets | 154.69M | 71.08M | 60.93M | 139.16M | 221.60M | 36.32M | 62.72M |
| Total Debt | 6.95M | 8.14M | 12.50M | 19.94M | 20.74M | 21.89M | 18.63M |
| Cash & Equiv | 137.53M | 55.29M | 44.70M | 120.39M | 198.05M | 19.24M | 48.84M |
| Book Value | 35.27M | 17.60M | 36.83M | 105.65M | 185.43M | (5.29M) | 38.51M |
| Return on Equity | -0.99 | -3.31 | -2.07 | -0.84 | -0.41 | N/A | -0.45 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.65M | 13.69M | 19.07M | 8.08M | 2.93M | 1.72M | 2.26M | 2.36M | 0 | 0 | 0 | 0 |
| Net Income | (9.53M) | 10.36M | (16.29M) | (15.84M) | (13.27M) | (13.09M) | (14.02M) | (13.93M) | (17.20M) | (17.66M) | (16.75M) | (19.36M) |
| EPS | -0.58 | 0.96 | -1.54 | -4.34 | -2.52 | -2.80 | -3.08 | -4.48 | -8.68 | -8.96 | -8.54 | -9.80 |
| Free Cash Flow | (22.90M) | (2.09M) | (17.50M) | (14.88M) | 28.96M | (14.16M) | (13.68M) | 19.93M | (10.50M) | (13.43M) | (13.37M) | (16.89M) |
| FCF / Share | -0.14 | -0.03 | -1.70 | -4.02 | 5.43 | -3.07 | -3.02 | 6.35 | -5.27 | -6.82 | -6.80 | -8.61 |
| Operating CF | (22.34M) | (2.00M) | (17.50M) | (14.48M) | 28.98M | (14.16M) | (13.67M) | 19.95M | (10.50M) | (13.43M) | (13.37M) | (16.57M) |
| Total Assets | 163.49M | 154.69M | 133.69M | 133.81M | 103.72M | 71.08M | 74.66M | 89.87M | 82.61M | 60.93M | 77.84M | 92.36M |
| Total Debt | 6.64M | 6.95M | 7.26M | 7.57M | 7.86M | 8.14M | 8.41M | 8.68M | 8.94M | 11.46M | 14.39M | 16.81M |
| Cash & Equiv | 150.33M | 137.53M | 103.76M | 121.55M | 89.07M | 55.29M | 61.26M | 74.95M | 33.98M | 44.70M | 59.77M | 75.38M |
| Book Value | 72.55M | 35.27M | (8.10M) | 7.07M | 10.70M | 17.60M | 20.97M | 33.42M | 25.77M | 36.83M | 52.50M | 67.38M |
| Return on Equity | -0.13 | 0.29 | N/A | -2.24 | -1.24 | -0.74 | -0.67 | -0.42 | -0.67 | -0.48 | -0.32 | -0.29 |
